List of Excipients in Branded Drug ESTRADIOL AND PROGESTERONE

« Back to Dashboard

Generic Drugs Containing ESTRADIOL AND PROGESTERONE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals NY LLC	estradiol and progesterone	69238-1690	FD&C RED NO. 40
Amneal Pharmaceuticals NY LLC	estradiol and progesterone	69238-1690	GELATIN
Amneal Pharmaceuticals NY LLC	estradiol and progesterone	69238-1690	GLYCERIN
Amneal Pharmaceuticals NY LLC	estradiol and progesterone	69238-1690	GLYCERYL MONOCAPRYLOCAPRATE
Amneal Pharmaceuticals NY LLC	estradiol and progesterone	69238-1690	LAUROYL PEG-32 GLYCERIDES

What are the Most Frequently-Used Excipients in ESTRADIOL AND PROGESTERONE?

# Of NDCs	Excipient
1	FD&C RED NO. 40
1	GELATIN
1	GLYCERIN
1	GLYCERYL MONOCAPRYLOCAPRATE
1	LAUROYL PEG-32 GLYCERIDES

Estradiol and Progesterone Excipient Strategy, Patent Protection, and Commercial Opportunities

Last updated: October 28, 2026

Estradiol and progesterone products have a clear formulation opportunity: combine two poorly water-soluble hormones in a fixed-dose, oral dosage form while controlling food effects, content uniformity, stability, capsule performance, and patient safety. The leading U.S. reference product is Bijuva, a softgel capsule containing 17β-estradiol and micronized progesterone in two strengths: 0.5 mg/100 mg and 1 mg/100 mg.[1]

The strongest commercial opportunities are peanut-free lipid formulations, improved oral bioavailability, lower-cost generic softgels, flexible dose combinations, transdermal or vaginal delivery, and manufacturing platforms that reduce hormone-handling risks.

What estradiol and progesterone products are commercially available?

Bijuva is the principal U.S. fixed-dose oral product containing estradiol and progesterone. FDA approved it in 2018 for moderate-to-severe vasomotor symptoms associated with menopause in women with a uterus.[1]

Product	Active ingredients	Dosage form	Key commercial positioning
Bijuva	Estradiol 0.5 mg/progesterone 100 mg	Oral softgel capsule	Continuous combined menopausal hormone therapy
Bijuva	Estradiol 1 mg/progesterone 100 mg	Oral softgel capsule	Higher estradiol strength
Estradiol tablets	Estradiol, commonly 0.5 mg, 1 mg or 2 mg	Immediate-release tablet	Estrogen-only therapy
Prometrium and generic micronized progesterone	Progesterone, commonly 100 mg or 200 mg	Oral capsule	Separate progesterone therapy
Estradiol transdermal systems	Estradiol	Patch, gel, spray or emulsion	Avoids first-pass hepatic metabolism
Compounded combinations	Variable	Capsules, creams, troches or other forms	Custom dosing, generally outside the FDA-approved product framework

Bijuva’s fixed-dose format reduces the need for patients to manage separate prescriptions. Its principal limitation is that the product offers only a small number of estradiol-to-progesterone ratios. That limitation creates room for dose-flexible and alternative-delivery products.

What excipients are used in Bijuva?

Bijuva uses a softgel system built around a lipid vehicle and a gelatin shell. FDA labeling identifies peanut oil among the inactive ingredients, together with capsule-shell and colorant components.[1]

The formulation architecture is commercially important because both estradiol and progesterone have low aqueous solubility. Progesterone is particularly difficult to formulate as a conventional aqueous product. A lipid vehicle can improve dispersion and support absorption after oral administration.

Formulation element	Likely function	Commercial significance
Peanut oil	Lipid vehicle for hormone dispersion and absorption	Creates an allergy and supply-chain limitation
Gelatin	Softgel shell former	Supports hermetic sealing and liquid-fill processing
Glycerin	Plasticizer and shell flexibility agent	Controls capsule mechanical properties
Sorbitol	Shell formulation and moisture-control component	Affects shell stability and brittleness
Titanium dioxide and colorants	Appearance and product identification	Supports differentiation and dose recognition

The exact qualitative and quantitative composition must be assessed against the current FDA labeling and product specifications before development decisions are made. Excipient selection can affect dissolution, food effect, oxidation, shell migration, fill viscosity, and manufacturing yield.

Why does peanut oil matter in the excipient strategy?

Peanut oil is the most visible vulnerability in the Bijuva formulation. A peanut-derived excipient can narrow prescribing comfort for patients with peanut allergy and complicate global commercialization where allergen labeling requirements differ.

A peanut-free product could create a distinct commercial position if it demonstrates equivalent or superior exposure and tolerability. Candidate lipid vehicles include:

• Medium-chain triglycerides
• Soybean oil
• Sunflower oil
• Corn oil
• Refined olive oil
• Caprylic and capric triglyceride systems
• Mixed lipid and surfactant vehicles

A replacement vehicle must be evaluated for hormone solubility, oxidation, peroxide formation, fill viscosity, capsule compatibility, and pharmacokinetic equivalence. Switching from peanut oil is not a simple excipient substitution. Changes in lipid composition can alter dispersion in the gastrointestinal tract and systemic exposure.

A peanut-free formulation could support a 505(b)(2) strategy when the sponsor can rely partly on the reference product’s safety and efficacy data while generating bridging studies for the new formulation.[2]

What excipient platform is best for estradiol and progesterone?

The most commercially credible platform remains a lipid-filled softgel, but the optimal design depends on the target market.

Lipid-filled softgels

Softgels are well suited to low-dose, lipophilic compounds. They provide:

• High content uniformity at microgram-to-milligram hormone loads
• Reduced powder segregation
• A compact dosage form
• Compatibility with lipid and self-emulsifying systems
• Potentially improved dissolution compared with conventional tablets

The key development risks are fill leakage, shell brittleness, cross-linking, oxygen sensitivity, and long-term migration of fill components into the gelatin shell.

Self-emulsifying drug-delivery systems

A self-emulsifying system could improve hormone dispersion after ingestion and reduce dependence on bile-mediated solubilization. The system may combine a lipid, surfactant, and cosurfactant.

This approach has commercial value if it reduces food-effect variability or permits a smaller capsule. It also creates a stronger formulation patent position than a basic oil-filled softgel. The development burden is higher because surfactant tolerability, capsule compatibility, and in vitro-to-in vivo correlation require careful control.

Solid dispersions and amorphous systems

Solid dispersions can improve dissolution but may be less attractive for progesterone because of physical instability and recrystallization risk. A tablet or capsule containing an amorphous dispersion could reduce dependence on a liquid fill, but it would require strong stability data.

Lipid-free tablets

A lipid-free tablet could reduce excipient cost and simplify manufacturing. The tradeoff is that estradiol and progesterone may require particle engineering, surfactants, complexation, or precipitation inhibitors to achieve consistent exposure.

Transdermal systems

Transdermal estradiol is commercially established. Progesterone is more difficult to deliver through skin at clinically adequate systemic exposure. A combined patch would need to address differences in dose, molecular transport, skin permeation, adhesive performance, and stability.

A more realistic opportunity may be a dual-product regimen: transdermal estradiol plus oral or vaginal progesterone. A true combined patch could be differentiated, but it would require substantial formulation and clinical development.

What formulations are protected by patents?

Bijuva’s core intellectual property is directed to combinations of estradiol and progesterone and associated pharmaceutical compositions. U.S. Patent No. 9,205,042 has been publicly associated with the Bijuva product and has an expiration date reported in public patent databases in 2032.[3]

IP category	Relevance to estradiol/progesterone products	Risk for competitors
Fixed-dose combination composition	Covers co-formulation of estradiol and progesterone	High for closely similar oral products
Softgel and lipid vehicle	May protect the dosage-form architecture	Depends on claim scope and prosecution history
Micronized progesterone	Can affect particle size and dissolution strategy	Moderate; design-around may be possible
Dose ratios	May limit direct copies of marketed strengths	Lower if alternative ratios are claimed differently
Method of treatment	Can cover menopausal hormone therapy use	Relevant to labeling and induced-infringement analysis
Manufacturing process	May protect filling, blending or encapsulation steps	Important for contract manufacturers

Patent strength depends on claim construction, prosecution history, written-description support, and whether later-filed patents cover specific excipient systems. A competitor using a different oil, capsule material, dose ratio, or delivery route may reduce composition-claim risk, but it still must assess method-of-use and formulation claims.

When does estradiol and progesterone lose exclusivity?

Bijuva’s principal listed patent protection has been associated with an expiration date in 2032. FDA regulatory exclusivity is separate from patent protection and generally expires earlier than the relevant patent term.

Bijuva received approval in 2018. Its original new-drug exclusivity period was shorter than the reported patent term, meaning generic or 505(b)(2) competition is primarily a patent and regulatory strategy question rather than a remaining clinical-exclusivity question.[1,4]

Protection type	Bijuva relevance
FDA approval	2018
New-drug exclusivity	Expired before the reported core patent expiration
Orange Book patent term	Publicly reported through approximately 2032 for the principal listed patent
Pediatric exclusivity	Must be confirmed from current FDA records
Generic entry	Depends on ANDA certification, patent litigation and settlement terms
505(b)(2) entry	May be possible for a different formulation, route, strength or excipient system

The commercial entry date could occur before patent expiration if a challenger obtains a favorable court result, enters under a settlement agreement, or develops a product that does not infringe valid claims.

Which companies are challenging estradiol and progesterone exclusivity?

The U.S. market contains extensive generic competition for estradiol and micronized progesterone as separate products. The principal competitive gap is the lack of broad fixed-dose generic competition for the combined Bijuva product.

An ANDA challenger would likely need to match the reference product’s active ingredients, strengths, dosage form, route, and performance characteristics. The softgel format and lipid vehicle can make bioequivalence more complex than a conventional tablet.

Potential challenger categories include:

1. Generic manufacturers with softgel capacity.
2. Hormone-replacement-therapy companies with existing estradiol or progesterone portfolios.
3. 505(b)(2) developers pursuing peanut-free or modified-release products.
4. Specialty pharmaceutical companies targeting menopause and women’s health.
5. Compounding pharmacies, although compounded products do not provide the same FDA-approved substitution pathway as an ANDA product.

No conclusion about a specific Paragraph IV filing should be drawn without reviewing current FDA Orange Book records, FDA Paragraph IV correspondence, and federal court dockets.

What is the Orange Book status of Bijuva?

Bijuva is an FDA-approved prescription drug listed in FDA drug databases. Its Orange Book position is relevant because listed patents can support a patent-certification requirement for ANDA applicants.[4]

For commercial diligence, the relevant questions are:

• Which patents are currently listed?
• Which strengths and dosage forms are covered?
• What are the listed patent expiration dates?
• Has any applicant filed a Paragraph IV certification?
• Has the patent owner filed an infringement action within the statutory period?
• Is a 30-month stay applicable?
• Does a settlement permit an earlier generic launch?

The Orange Book does not by itself establish that a listed patent is valid or infringed. Patent validity and infringement remain matters for litigation, settlement, or regulatory certification procedures.

What generic launch risks exist?

A generic Bijuva entrant faces four major technical barriers.

Bioequivalence

The applicant must show that the estradiol and progesterone exposures are comparable to the reference product. Separate evaluation of both hormones may be necessary because they have different absorption characteristics and pharmacokinetic variability.

Food effect

Lipid formulations can show meaningful fed-versus-fasted differences. A generic must control the relationship between food intake, capsule dispersion, hormone solubilization, and systemic exposure.

Softgel manufacturing

The process requires precise control of fill weight, viscosity, deaeration, encapsulation, sealing, drying, and shell moisture. Small process changes can affect dissolution and leakage.

Hormone containment

Estradiol and progesterone are potent active ingredients. Manufacturing facilities need validated containment, cleaning, cross-contamination controls, occupational exposure controls, and dedicated or segregated equipment where appropriate.

These barriers favor established softgel manufacturers and contract development and manufacturing organizations with hormone-handling experience.

What licensing deals could accelerate market entry?

Licensing opportunities are strongest where a sponsor has one component of the development platform but lacks the other.

Asset holder	Potential partner	Deal rationale
Peanut-free lipid formulation	Women’s health company	Adds differentiation to an established commercial category
Softgel manufacturing platform	Generic manufacturer	Reduces technical and scale-up risk
Transdermal progesterone technology	Estradiol patch company	Supports a combined hormone-delivery program
Micronization or particle-engineering technology	505(b)(2) sponsor	Improves dissolution and supports formulation claims
Regional menopause portfolio	Global pharmaceutical company	Expands geographic distribution
Approved Bijuva commercial rights	Specialty pharmaceutical company	Provides an established product without full development risk

A license should distinguish composition claims, manufacturing know-how, regulatory data rights, territorial rights, and freedom-to-operate obligations. Formulation know-how can be as valuable as issued patents in this category because softgel manufacturing performance is difficult to reproduce from patent disclosures alone.

How does estradiol and progesterone compare with competing hormone therapies?

Attribute	Oral estradiol/progesterone	Separate oral products	Transdermal estradiol plus progesterone	Compounded therapy
Patient convenience	High	Lower	Moderate	Variable
Dose flexibility	Limited by fixed combinations	High	High for estradiol, variable for progesterone	High
First-pass metabolism	Present	Present	Avoided for estradiol	Depends on route
Peanut-free availability	Formulation-specific	Usually more options	Usually not relevant to patch	Variable
FDA-approved evidence	Available for approved product	Available separately	Available by component	Generally limited for the compounded combination
Generic competition	Limited for fixed combination	Extensive	Broad for estradiol, less uniform for combinations	Not an ANDA market
Formulation opportunity	High	Moderate	High for combined delivery	High but regulatory value is limited

The fixed-dose combination has a convenience advantage. Separate products have greater dosing flexibility and broader generic availability. Transdermal therapy has a differentiated pharmacokinetic profile, but a combined estradiol/progesterone patch remains technically more difficult.

What is the revenue opportunity for new excipient strategies?

Public company disclosures do not consistently report Bijuva revenue as a standalone line item. The market opportunity should therefore be modeled from prescription volume, net price, payer coverage, persistence, and share capture rather than from a single publicly reported product figure.

The most defensible commercial segments are:

• Patients who cannot use peanut oil.
• Patients seeking a single daily capsule.
• Patients dissatisfied with separate estrogen and progesterone prescriptions.
• Lower-cost generic or authorized-generic users.
• Menopause-focused telehealth and specialty pharmacy channels.
• International markets where fixed-dose hormone therapy is established.
• Patients requiring a nonoral route because of tolerability or risk-management considerations.

A peanut-free product could command a premium only if it demonstrates clear clinical or practical value. A generic softgel would compete mainly on price, supply reliability, payer access, and equivalence. A new delivery system would require stronger differentiation but could preserve pricing power for longer.

Key Takeaways

• Bijuva is the principal U.S. fixed-dose oral estradiol/progesterone product.
• Its softgel uses a lipid-based formulation and includes peanut oil, creating a commercially relevant excipient vulnerability.
• Peanut-free lipid vehicles are the clearest near-term formulation opportunity.
• Self-emulsifying systems, alternative oils, and solid-dispersion technologies could support new composition patents.
• The principal publicly associated Bijuva patent protection extends to approximately 2032, subject to current Orange Book and patent-record verification.
• Generic entry is technically harder than for conventional estradiol tablets or progesterone capsules because of softgel processing, food effect, and dual-hormone bioequivalence.
• The strongest licensing targets are peanut-free formulations, softgel manufacturing platforms, transdermal progesterone technologies, and regional women’s-health portfolios.
• Separate generic estradiol and progesterone products remain the main competitive alternative to the fixed-dose combination.

FAQs

Can peanut oil be replaced without changing the regulatory pathway?

A replacement may support a 505(b)(2) application or another regulatory pathway, depending on the extent of formulation and pharmacokinetic differences. The sponsor would need to establish product quality, comparative exposure, safety, and manufacturing control.

Is a fixed-dose estradiol/progesterone tablet easier to develop than a softgel?

No. A tablet may simplify shell manufacturing, but low solubility, dose uniformity, dissolution, and hormone stability can become more difficult. The best dosage form depends on the selected solubilization technology.

Could a generic use a different oil from Bijuva?

Potentially. A different oil may reduce literal infringement risk for formulation claims, but the applicant would still need to assess other composition, method-of-use, process, and regulatory requirements.

Is vaginal progesterone a direct substitute for oral progesterone in a combined product?

Not automatically. Route, dose, exposure, labeling, clinical evidence, and regulatory status differ. A vaginal product would require its own formulation and clinical strategy.

What is the strongest patent strategy for a new estradiol/progesterone product?

A layered strategy combining a novel lipid or self-emulsifying system, defined hormone particle characteristics, specific dose ratios, manufacturing controls, and treatment methods generally provides broader protection than relying on a basic fixed-dose combination claim alone.

References

1. U.S. Food and Drug Administration. (2018). Bijuva (estradiol and progesterone) capsules prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA.

3. U.S. Patent No. 9,205,042. (2015). Pharmaceutical compositions comprising estradiol and progesterone. U.S. Patent and Trademark Office.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.